All reports.

Moove

Moove has reported substantial operating scale and a $2.1 billion Series C valuation, but unverified earnings, capital needs, and partner exposure make investment approval premature.

Valuation

$2.1B

ARR

$420M

Mark43

Mark43 has meaningful public-sector reach and a broad mission-critical platform, but undisclosed economics, ambiguous customer metrics, and unpriced acquisition terms leave valuation and returns ununderwritable.

LigaChem Biosciences

LigaChem’s partnered ADC platform and selective in-house clinical progress offer meaningful optionality, but losses, uncertain cash runway, contingent deal economics, and the absence of a defensible current valuation support research-more rather than a high-conviction entry.

LifeMine Therapeutics

LifeMine's 2026 financing and ongoing Phase 1 program merit tracking, but undisclosed transaction terms, liquidity, and independent clinical outcomes leave valuation and entry price unassessable.

Kredivo

Kredivo combines established digital-credit scale and banking optionality, but missing parent economics, credit cohorts, and a current entry price support further diligence rather than an investment commitment.

Ivalua

Ivalua has a credible, broad enterprise source-to-pay platform, but undisclosed current economics, transaction terms, and governance prevent a high-conviction valuation call; further diligence is warranted.

Humanity Protocol

Humanity Protocol has product activity and identity-market optionality, but the 2026 key compromise, unproven commercial conversion, and absent current financial disclosure keep the recommendation at research-more.

Cambridge Mobile Telematics

CMT has a scaled telematics platform and strategic validation, but opaque economics and an unverified cyber allegation support further diligence rather than an entry decision.

Volta

Volta's financing-led AI-factory model is differentiated, but public evidence supports research-more discipline rather than underwriting its reported $2.4 billion valuation.

Valuation

$2.4B

Our Next Energy (ONE)

ONE's LFP platform and customer activity support continued diligence, but delivery conversion, current unit economics, financing terms, and liquidity remain unverified.

Moss

Moss has reported late-stage scale and an integrated finance workflow, but conflicting financing disclosures and unverified unit economics, retention, and capital terms leave the €1.0bn mark too difficult to underwrite for a buy.

Manner Coffee

Reported scale and a compact, value-oriented format merit continued diligence, but financial opacity, execution risks, and the absence of a verified current valuation preclude an investment call.

EcoFlow

EcoFlow has broad product reach and reported scale, but private-company economics, current valuation, and safety exposure remain too unverified for an underwritten entry.

Obsidian Security

Obsidian pairs substantial enterprise-spend signals with a credible AI-agent-governance position, but opaque recurring economics make its $1.1 billion mark difficult to underwrite and favor tracking over conviction pricing.

Valuation

$1.1B

HappyRobot

HappyRobot has meaningful reported enterprise adoption and a $1.2 billion Series C mark, but opaque financials and unverified operating outcomes support a track recommendation at a stretched valuation.

Valuation

$1.2B

Haomo Zhixing Technology Co., Ltd.

Avoid at an unverified entry price until current operations, solvency, customer commitments, and capitalization are independently established.

Guangzhou Juwan Technology Co., Ltd.

Historical XFC product and plant milestones are credible diligence leads, but current operating economics, customer performance, and financing terms are too weakly evidenced to support a priced investment.

Abogen Biosciences

Abogen has added a reported Phase III shingles program and a proposed Novartis license, but limited clinical outcomes, commercial evidence, and private financial disclosure still prevent a price-supported investment case.

Xsight Labs

Xsight has credible product and design-in signals, but its $2.8 billion financing mark remains difficult to underwrite without revenue, margin, customer-conversion, and capital-structure denominators.

Valuation

$2.8B

Xingchen General Robot

The public record supports a research-more decision, not price underwriting: early product and partnership signals remain unaccompanied by verified financing terms, paid-customer durability, current financials, or deployment performance.

Xiaohongshu

Research more before pricing: Xiaohongshu has differentiated search-led discovery and reported scale, but the available evidence does not support an investable entry price.

Growth

40%

TruKKer

TruKKer has a documented regional freight platform and financing access, but opaque economics, receivables performance, customer quality, and equity terms support a research-more stance rather than a priced investment.

OrCam Technologies

OrCam has a credible assistive-technology proposition, but reported revenue contraction and unresolved financing terms leave current commercialization and equity value unproven.

Neo Group

Neo's reported asset scale and investor backing warrant further diligence, but inconsistent transaction disclosures, limited financial visibility, and an unverified regulatory perimeter prevent a defensible entry valuation.

HeyTea

HeyTea has a differentiated product and reported global scale, but current economics, customer durability, and valuation cannot be underwritten from available public evidence.

Genki Forest

Genki Forest has meaningful beverage scale and recent reported operating progress, but opaque current financials and entry terms prevent a defensible price-sensitive investment decision.

DayOne Data Centers

DayOne shows meaningful scale and capital access, but concentrated customers, opaque economics, and unsettled IPO terms make the reported target difficult to underwrite.

Growth

238%

CertiK

Product breadth and named customer examples support continued diligence, but public evidence does not establish recurring economics, control effectiveness, or a defensible current entry valuation.

Zerodha

Track Zerodha as a high-quality, profitable brokerage, but do not underwrite a buy without current price evidence, reconciled segment economics, and durable customer cohorts.

Growth

-11.5%

Purplle

Purplle has credible reported scale and a differentiated multi-brand model, but conflicting financial evidence and unverified transaction economics warrant further diligence before an investment decision.

National Resilience, Inc. (Resilience)

Research-more: Resilience has meaningful Lilly-linked production and a focused CDMO platform, but undisclosed financials, leverage, utilization, and customer economics prevent a confident valuation.

Molbio Diagnostics

Truenat's installed base and FY26 growth support a credible diagnostics platform, but demand concentration, cash-conversion uncertainty, and public-market pricing risk keep the recommendation at Track.

Valuation

$1.5B

Growth

41.7%

Flink

March 2026 growth capital and reported EBITDA profitability support an operating recovery, but unverified cash conversion, financing terms, and the scope of a September 2026 data incident keep the recommendation at research-more.

boAt

boAt has category scale and a reported earnings recovery, but audit-control concerns, customer concentration, and unpriced IPO terms warrant a price-disciplined track stance.

Zhiyuan Robot

Zhiyuan is a credible China humanoid frontrunner with meaningful deployment and shipment evidence, but public economics and financing terms do not yet support a buy call.

Valuation

$2.1B

XREAL

XREAL has credible category and platform traction, but negative cash generation and incomplete financing disclosure justify tracking rather than buying.

Valuation

$1B

Tyme Group

Tyme Group has credible emerging-market digital-banking traction and a South African profitability proof point, but incomplete consolidated financial, ownership, and current-price disclosure supports tracking rather than a high-confidence buy recommendation.

Valuation

$1.5B

Octopus Energy

Octopus Energy has credible retail scale and a valuable Kraken software option, but the investment case remains execution- and disclosure-constrained.

Growth

10%

Micro Connect

Track: Micro Connect has differentiated financing infrastructure and visible deployment, but public disclosure remains too thin to underwrite current economics or valuation.

Valuation

$1.7B

Kry

Kry has credible hybrid-care scale and improving operating indicators, but unresolved financing, liquidity and retention disclosure keeps the opportunity in track territory.

Fresh Life Cold Chain

Fresh Life Cold Chain has credible operating scale and financing access, but opaque financials and financing terms make the current investment case price-uncertain.

Erebor Bank

Erebor may become a valuable frontier-sector banking franchise, but current public evidence does not justify underwriting reported valuation talk without deeper diligence and price discipline.

Digital Edge

Digital Edge appears strategically credible and likely valuable, but public evidence still supports RESEARCH-MORE rather than a conviction-priced entry at an unknown valuation.

Aether Intelligence

Aether may be a serious regional enterprise-AI company, but unresolved identity and weak primary disclosure make the reported valuation and operating scale uninvestable without further verification.

Valuation

$1B

NRR

158%

Coda Payments

Coda has differentiated gaming-native payments and commerce scale, but current price, combined profitability, and post-Recharge economics are not sufficiently disclosed for an investment decision.

Collate

Collate has a credible regulated-workflow wedge and strong financing momentum, but the reported near-$1 billion valuation remains stretched until recurring economics and financing terms are verified.

Valuation

$1B

Treeline Biosciences

Treeline combines experienced oncology founders and substantial disclosed funding with a still-unvalidated clinical platform, so the appropriate stance is research-more pending transaction, financial, and human efficacy evidence.

PatSnap

PatSnap looks like a real scaled innovation-intelligence platform with credible recurring-revenue signals and IPO optionality, but public-only evidence still supports research-more until financial, retention, governance, and offering terms are verified.

Valuation

$2B

ARR

$140M

CoinDCX

CoinDCX shows meaningful scale and financing access, but current economics and control evidence do not support underwriting beyond research-more.

Valuation

$2.5B

Simile

Simile has differentiated research lineage and early enterprise traction, but its $2 billion valuation remains difficult to underwrite without private operating and financing disclosures.

Valuation

$2B

Reliable Robotics

Reliable Robotics has credible autonomy, certification, and financing progress, but its above-$1 billion private mark remains difficult to underwrite before commercial certification and operating economics are disclosed.

Quantum Space

Quantum Space has credible government-market traction, but its proposed valuation remains ahead of flight proof, funded-backlog visibility, and operating-data disclosure.

Valuation

$1.2B

Myricx Bio

A scientifically differentiated but still binary preclinical ADC platform whose announced Novartis transaction validates strategic scarcity more than clinical proof; track pending closing and human translation.

Valuation

$1.5B

Moqi Intelligent Technology

Moqi is credible enough to track because its founders, financing signals, and humanoid-robotics position are real strengths, but the roughly $1 billion reference remains unproven without commercial and financial disclosure.

Valuation

$1B

Moneybox

Moneybox is a scaled and profitable consumer wealth platform, but the £800 million secondary-market mark is fair rather than clearly attractive until primary economics and transaction terms are disclosed.

Valuation

$1.1B

Growth

52%

Kraken Technology Group

Kraken has credible sovereign-customer and strategic-financing signals, but the public record does not disclose the operating denominators needed to underwrite its reported valuation.

Valuation

$1B

Kela Technologies

Kela has credible early deployment and financing momentum, but its private valuation already assumes substantial execution and allied-market expansion that public operating evidence does not fully underwrite.

Valuation

$1.2B

Foodics

Foodics has credible regional scale and product breadth, but incomplete financial, retention, and control disclosure supports tracking rather than buying.

Growth

29%

Elroy Air

Elroy Air has differentiated autonomous cargo-aircraft technology and meaningful strategic validation, but public disclosure remains too thin on commercial conversion, operating economics, and transaction cash mechanics to support a high-conviction investment.

Valuation

$1B

Eliyan

Eliyan appears strategically relevant and technically differentiated, but the visible unicorn valuation still runs ahead of the visible operating proof.

Valuation

$1B

EigenQ

EigenQ occupies an attractive quantum-safe infrastructure wedge, but the proposed approximately $3 billion SPAC valuation still outruns the public evidence on operating scale and supports research-more rather than conviction buying.

Valuation

$3B

Cover Genius

Cover Genius has credible global embedded-insurance scale and partner proof, but public disclosure remains too thin on economics, concentration, financing terms, and security assurance to underwrite the USD 1.9 billion mark with high confidence.

Valuation

$1.9B

Growth

50%

Carousell

Carousell merits close tracking and serious diligence because FY25 growth, rising recommerce mix, and positive EBITDA improve the operating case, but the lack of a current price, audited unit economics, and complete risk disclosure prevents a high-conviction investment recommendation.

Valuation

$1.1B

Revenue run-rate

$141M

Growth

18%

Ajaib

Ajaib combines credible retail scale, broadening product coverage, and a fresh strategic financing signal, but disclosure gaps keep risk-adjusted valuation underwriting incomplete.

Growth

152%

Princeton Digital Group

Research more: PDG has credible APAC infrastructure scale and institutional financing access, but public evidence remains insufficient to underwrite current economics, leverage, or valuation.

Morpho Labs

Morpho has credible potential as embedded onchain credit infrastructure, but the investment case remains blocked on monetization, entity-level financials, token rights, and concentration evidence.

Valuation

$2B

Main Func

Main Func shows a meaningful AI-workspace growth story, but its reported $2.6 billion valuation requires verified retention, margins, customer quality, and financing terms before investment.

Valuation

$2.6B

Revenue run-rate

$250M

Crimson Education

Crimson has real scale and a differentiated education portfolio, but conflicting valuation marks and limited financial disclosure keep the opportunity in research-more territory rather than a conviction-priced entry.

Castelion

Track Castelion: strategic demand and financing are credible, but public evidence does not yet support aggressive pricing without verified procurement conversion, factory execution, and unit economics.

Assured

Assured appears to be a credible vertical-AI claims platform, but the public record does not yet support underwriting its reported $1 billion financing valuation.

Valuation

$1B

Antares Nuclear

Antares has cleared an important hardware milestone and has identifiable government demand, but commercial reliability, licensing, economics, and valuation remain unproven.

Vast

Vast has credible generative-3D product traction and category momentum, but opaque economics and conflicting financing disclosures make it a tracking opportunity rather than an underwritable buy.

Valuation

$1.5B

Pasqal

Pasqal has credible neutral-atom technology, installed systems, and commercialization pathways, but the gap between public-market expectations and disclosed revenue, renewal, and production economics warrants further research.

Valuation

$2B

Ominimo

Ominimo shows unusually rapid European motor-insurance growth and strong carrier-backed distribution, but the reported unicorn valuation still outruns the quality of public disclosure on retained economics, governance, and licensing scale-up.

Valuation

$1.6B

Revenue run-rate

$350M

Neo Security

Neo Security has a credible agentic-security thesis and strong reported funding, but insufficient public customer, financial, and technical proof for more than a track/research-more stance.

Locus Robotics

Track: Locus has substantial enterprise traction and a credible path from collaborative AMRs to broader warehouse automation, but private-company opacity and unverified current economics do not support an aggressive valuation conclusion.

Revenue run-rate

$180M

ARR

$180M

Growth

9.1%

Lila Sciences

Lila is a well-capitalized AI-for-science platform with credible system-level ambition, but the public record has not yet shown repeatable commercial or scientific proof sufficient to underwrite a premium valuation.

Valuation

$1.3B

Keyuan Petrochemicals

Keyuan appears to be a substantial operating industrial group, but the public record supports deeper diligence more than conviction pricing.

DriveNets

DriveNets has credible production-network and financing signals, but the reported valuation remains stretched until private operating and capitalization data are disclosed.

Valuation

$8.5B

Ionic Digital

Ionic Digital has a credible contracted AI-infrastructure anchor, but customer concentration, cash-conversion evidence, expansion execution, and dilution keep the opportunity in research-more territory.

Valuation

$2.4B

Revenue run-rate

$193M

Crystalys Therapeutics

Crystalys has a credible late-stage gout asset and substantial disclosed financing, but unresolved clinical, regulatory, capitalization, and launch economics support track rather than a priced-in buy.

AI21 Labs

Track: AI21 has credible enterprise-AI technology and customer evidence, but the historical valuation and limited operating disclosure leave too little public margin of safety for a higher-conviction recommendation.

Valuation

$1.4B

PointClickCare

PointClickCare has a strong post-acute care platform position, but incomplete private-company disclosures and unresolved information-blocking litigation keep the underwriting case in research-more territory.

Pigment

Pigment has credible enterprise-planning traction and a major 2026 financing, but insufficient public operating and deal-term disclosure supports only a price-sensitive research-more stance.

Valuation

$2.3B

Kurly

Kurly's profitability inflection and partner-channel growth improve the case, but thin margins, opaque liquidity, and competitive pressure make the current stance track rather than buy.

Growth

28.4%

Flex

Flex has credible product breadth and financing momentum, but the reported valuation still depends on unverified revenue quality, credit performance, customer durability, and global-control execution.

Valuation

$1.2B

Dongchedi

Dongchedi has credible automotive-platform reach and ByteDance-linked distribution, but opaque economics, governance, and trust risks keep the reported $3 billion private valuation at a research-more, information-discounted stance.

Valuation

$3B

DataSnipper

DataSnipper has a credible Excel-native audit automation wedge and strong customer validation, but the $1 billion private valuation still requires current financial, retention, margin, and AI-quality diligence before an investable conclusion.

Valuation

$1B

ARR

$45M

Yubi

Yubi is a strategically credible debt-infrastructure unicorn, but the current private mark should be approached with discipline because public proof on monetization, concentration, cash economics, and regulatory cleanliness still lags the platform story.

Valuation

$1.5B

Vivriti Capital

Vivriti looks like a scaled Indian mid-market credit franchise, but leverage, concentration and incomplete post-reorganisation transparency keep the recommendation at track rather than buy.

Growth

28.9%

VerSe Innovation

VerSe Innovation is a scaled Bharat media asset with improving reported FY25 economics, but stale price discovery, governance overhang, and thin product-level disclosure keep the investable call at track rather than buy.

Growth

88%

Path Robotics

Path Robotics has credible product, customer, and market proof, but public evidence remains too opaque on economics and current pricing for price-insensitive underwriting.

Newsela

Newsela has a credible differentiated-content and district-workflow position worth tracking, but public evidence does not support a current buy at an unknown private-market price.

Cedar

Cedar shows credible healthcare enterprise adoption and product breadth, but undisclosed current financial quality and retention keep the investment stance at research-more.

Valuation

$3.2B

Ai.tech

Ai.tech has strategically relevant ad-tech assets and a reported bootstrapped-unicorn valuation, but weak operating disclosure leaves the investment case in research-more territory.

Valuation

$1.5B

Talkdesk

Talkdesk shows credible enterprise scale and an active AI transition, but incomplete current economics and capital-structure evidence keep the historical valuation from being underwritten.

Valuation

$10B

Icertis

Icertis appears to be a scaled enterprise contract-intelligence asset with durable workflow relevance, but incomplete public metrics and uncertain current price discovery require continued diligence.

ARR

$300M

Prague Technology

Prague Technology merits tracking rather than a buy because founder and sector context are credible but company identity, commercialization, financing terms, and valuation remain insufficiently verified.

Pump

Pump has a differentiated, low-friction cloud-cost proposition and credible reported scale, but the public evidence is not sufficient for a confident investment decision without verified economics, controls, and financing terms.

Valuation

$1.5B

Revenue run-rate

$15.2M

HiBob

HiBob has credible product breadth and strategic momentum, but the reported premium valuation remains only partially underwritten until audited operating metrics and capitalization terms are disclosed.

Valuation

$3.2B

Revenue run-rate

$400M

ARR

$197M

Cockroach Labs

Cockroach Labs is a credible late-stage distributed-database platform with real enterprise adoption, but the current private-market price cannot be underwritten confidently without updated financial disclosure.

Valuation

$5B

Checkmarx

Checkmarx has meaningful enterprise scale and platform breadth, but incomplete financial and retention disclosure prevents high-conviction underwriting.

Valuation

$2.5B

ARR

$150M

Celero Communications

Celero has credible technical and financing momentum, but its reported valuation remains difficult to underwrite without current operating, customer, unit-economic, and capitalization evidence.

ZeroAvia

ZeroAvia has a credible, strategically backed hydrogen-electric platform, but certification timing, financing transparency, and commercial conversion do not yet support a buy decision.

Valo Health

Valo Health has credible strategic-partner validation, but clinical attrition and opaque current financing support a research-more decision.

Svante Technologies

Svante has credible technology, manufacturing scale-up, and strategic backing, but unresolved project-finance, commercial-revenue, liquidity, and valuation evidence warrants a research-more stance.

NotCo

NotCo has credible AI-enabled food-formulation differentiation and partner traction, but current valuation support and operating resilience remain too opaque for more than a track recommendation.

Valuation

$1.5B

Revenue run-rate

$75M

Meshy

Meshy has strong reported scale and product accessibility, but a stretched financing valuation and incomplete independent evidence on monetization make the opportunity a track rather than an immediate buy.

Valuation

$1.5B

Revenue run-rate

$100M

ARR

$100M

Flow

Flow has real operating substance and unusual financing access, but public evidence does not justify high-conviction comfort on governance, unit economics, or its reported $2.5 billion private valuation.

Valuation

$2.5B

Factorial

Factorial has credible European workforce-software scale and adoption signals, but private-company disclosure gaps make the current entry price and return case difficult to underwrite.

Crusoe Energy Systems

Crusoe has a differentiated power-first AI infrastructure platform, but the reported valuation still assumes successful hyperscale execution that public evidence does not fully underwrite.

Valuation

$30.9B

CloudWalk

CloudWalk shows strong reported growth and profitable multi-product expansion, but the investment case remains conditional on validating the durability and economics of its credit and FIDC funding engine.

Valuation

$2.2B

Revenue run-rate

$1.3B

ARR

$1.3B

Growth

104%

Cathedral

Cathedral has exceptional reported financing and investor backing, but its $1.4 billion valuation is not underwritten by public operating proof.

Valuation

$1.4B

Candid Health

Candid Health shows strong financing, growth, and adoption signals, but limited independent financial and customer evidence warrants deeper diligence before underwriting.

Growth

190%

NRR

180%

Cabify

Cabify shows credible mobility scale and a constructive reported profitability trajectory, but current valuation and cash-generation confidence remain too limited for an investment recommendation beyond further research.

Revenue run-rate

$858M

Betterfly

Betterfly merits continued diligence for its strategic platform and distribution assets, but current economics and capitalization are too opaque for a confident valuation call.

Valuation

$1B

Atoms

Atoms is a well-capitalized but opaque physical-automation platform whose public operating proof is not yet sufficient for a buy recommendation.

SiMa.ai

SiMa.ai is a credible, well-backed Physical AI silicon company, but its reported roughly USD1.45 billion valuation prices execution that is not yet independently visible, so the disciplined stance is research-more pending audited financials and stronger benchmark evidence.

Valuation

$1.5B

Psibot

Psibot combines a credible embodied-AI platform and strategic industrial backing with a high reported valuation, but insufficient public operating disclosure to support an investment decision.

Valuation

$1.5B

MGT

MGT is a credible, scaled SLED technology and advisory platform, but the investment case remains dependent on private diligence of audited economics, capital structure, customer durability, and acquisition quality.

Valuation

$1.3B

Matchroom

Matchroom is a strategically durable sports-rights and events platform, but opaque entry valuation and incomplete cash-flow disclosure make the appropriate stance research more.

Augustus

Augustus has a differentiated regulatory and infrastructure opportunity, but the conditional bank, limited operating disclosure, and unresolved control evidence support tracking rather than buying at the reported valuation.

Valuation

$1B

SiliconFlow

SiliconFlow appears to be a real and strategically relevant inference platform, but financing momentum is not yet matched by public evidence of durable margins, retention, reliability, or an investable price.

Evoken

Evoken has credible product breadth and reported scale, but public evidence does not yet verify durable high-margin ARR or clean shareholder economics.

Valuation

$2B

ARR

$300M

CuspAI

Track: CuspAI has credible technical and strategic validation, but the reported $2.6 billion mark still assumes commercial economics that public evidence does not establish.

Valuation

$2.6B

Bulage

Bulage may become an important China embodied-AI platform, but public evidence still does not justify underwriting the reported $2 billion valuation as a buy today.

Valuation

$2B

Aerospace Yuxing

Aerospace Yuxing has real product and customer proof, but the public record still supports tracking the company more than paying peak-narrative pricing.

Zyphra

Zyphra has unusually strong public technical and partner evidence for a private AI startup, but customer proof and economics disclosure remain too thin to justify price-insensitive underwriting.

Valuation

$1B

ARR

$8.8M

Zilch

Zilch has a differentiated, scaled consumer-payments platform and improving reported economics, but the current investment case remains price-sensitive because valuation, retention, liquidity, and post-regulation unit economics are not fully verifiable.

Growth

93%

StepStar

StepStar is a technically credible and well-funded foundation-model company with a distinctive multimodal-to-device strategy, but opaque economics, contested valuation marks, and unresolved commercialization risks support research-more rather than a buy.

Valuation

$10B

SHAREBOT

SHAREBOT addresses a credible robotics-adoption wedge, but opaque economics and a conditional valuation reference limit conviction.

Satispay

Satispay has built meaningful Italian payment-network scale and product breadth, but the public evidence does not yet support a confident view on unit economics, controls, or valuation.

Revenue run-rate

$125.5M

Growth

80%

Property Finder

Property Finder appears to be a strong regional property-marketplace asset with credible institutional backing and broad product reach, but private-financial opacity and unresolved marketplace-quality risks keep the stance at research-more rather than buy.

Origin Quantum

Origin Quantum is a credible full-stack quantum platform, but opaque financials, unverified customer economics, reliability gaps, and unreconciled financing terms support research-more rather than a buy.

DeepSeek

Track DeepSeek for technical leadership and demand momentum, but do not underwrite headline valuations until financial, financing, governance, and access risks are independently verified.

Corgi

Corgi shows strong reported growth and a differentiated full-stack insurance model, but limited underwriting, capital, and claims disclosure supports tracking rather than an immediate investment commitment.

Valuation

$2.6B

Revenue run-rate

$40M

ARR

$40M

Recursive

Recursive has exceptional technical and financing signals, but the $4.65 billion valuation remains unsupported by public revenue, customer, unit-economics, and governance evidence.

Valuation

$4.7B

Virta Health

Virta shows differentiated metabolic-care capabilities and stronger 2026 operating momentum, but the public record supports tracking rather than underwriting a new entry until private-market pricing, retention, margins, and risk disclosures improve.

Valuation

$2B

Revenue run-rate

$158M

ARR

$158M

Postman

Postman has durable API-workflow relevance and broad adoption signals, but insufficient public evidence on current economics, retention, governance, and valuation supports a research-more stance rather than underwriting at the 2021 peak mark.

Valuation

$5.6B

Mirakl

Mirakl has meaningful enterprise marketplace scale and a credible category position, but the dated private mark and incomplete financial disclosure support tracking rather than buying.

Valuation

$3.5B

ARR

$218M

Growth

23%

Lighter

Lighter has public scale, technical differentiation, and investor validation sufficient for continued diligence, but the reported $1.5 billion valuation is not cleared by public evidence because revenue quality, customer durability, and regulatory and operational resilience remain under-disclosed.

Valuation

$1.5B

Arena

Arena shows credible category leadership and commercial traction, but public evidence does not yet justify buy-level conviction at the reported valuation.

Valuation

$3.1B

Revenue run-rate

$100M

Aledade

Aledade has credible scale and adoption evidence, but current valuation, financial quality, debt utilization, and ownership economics remain too opaque for a buy decision.

Oxylabs

Oxylabs appears to be a scaled AI-era web-data infrastructure company, but the disclosed valuation leaves too little public-evidence edge for a buy call.

Valuation

$3.6B

Revenue run-rate

$350M

ARR

$350M

OriCell Therapeutics

OriCell has credible clinical and financing momentum in a difficult CAR-T segment, but the public record is not sufficient to underwrite valuation or commercial scale.

Neo Fusion

Neo Fusion is strategically important within China's fusion roadmap, but thin disclosure, unproven commercialization, and high milestone risk support a research-more recommendation.

Ledger

Ledger is strategically compelling and plausibly scalable, but the public record supports a track posture rather than aggressive premium underwriting.

Kin Insurance

Kin shows credible scale and improving underwriting in catastrophe-focused homeowners insurance, but the $2 billion mark remains a research-more case until carrier-level economics and security terms are disclosed.

Valuation

$2B

Revenue run-rate

$201.6M

Kairos Power

Kairos Power is a strategically credible advanced-nuclear platform, but public-only evidence supports a track stance rather than a buy because valuation and economics remain under-disclosed while first-of-a-kind execution risk stays high.

IM Motors

IM Motors is a credible, strategically backed premium EV contender, but public evidence supports tracking rather than underwriting a premium current valuation.

Fever

Track: Fever shows credible global scale, partner proof, and reported operating momentum, but the $5.2B private valuation remains only conditionally supportable without audited economics, retention, and concentration data.

Valuation

$5.2B

Destinus

Destinus has credible defense-product and partnership momentum, but public evidence does not yet justify underwriting the reported valuation target.

Alentis Therapeutics

Alentis has a coherent CLDN1 platform and meaningful partner validation, but limited human efficacy, valuation, and runway disclosure support a high-risk track posture.

Yangtze Memory Technologies

YMTC is a strategically important and commercially credible NAND manufacturer, but export controls, capital intensity, and opaque financial and customer disclosures keep conviction at track rather than buy.

WeDoctor

WeDoctor appears to be a strategically important China digital-health platform with meaningful operating scale, but incomplete current disclosure makes a confident investment decision premature.

Growth

107.4%

QuEra Computing

QuEra shows strong technical and deployment momentum, but opaque economics and financing terms support Track rather than Buy.

Valuation

$1B

Revenue run-rate

$39.9M

EXU

EXU has a high reported financing mark but insufficient public operating, customer, control, and transaction-term evidence to underwrite that valuation.

Valuation

$1.2B

Spectro Cloud

Spectro Cloud appears strategically relevant in AI infrastructure management, but the reported $1 billion-plus private valuation remains a research-more situation because public operating and economic proof is incomplete.

Valuation

$1B

Unisoc

Unisoc has meaningful communications-chip scale and market presence, but incomplete audited disclosure, governance history, and geopolitical exposure support a track recommendation rather than a buy call.

Chipper Cash

Chipper Cash has a broad payments platform and meaningful historical reach, but limited current disclosure supports a research-more stance rather than an investment endorsement.

Quwan

Quwan appears to be a scaled historical gamer-social asset with credible monetization, but stale operating disclosure and unverified transaction terms keep the investment case conditional.

Growth

-5.2%

Lumin Digital

Lumin Digital looks like a credible scaled digital-banking platform, but public disclosure is still too thin to underwrite the current private-market mark with high conviction.

Valuation

$1.6B

Fora

Fora has credible advisor and booking momentum, but its reported $1 billion valuation remains difficult to underwrite because revenue, margins, retention, and downside terms are not publicly disclosed.

Valuation

$1B

Envision Energy

Track Envision Energy: commercial scale and strategic breadth are credible, but disclosure, capital intensity, geopolitics, and valuation uncertainty prevent a fully underwritable investment case.

Valuation

$15B

Earendil Labs

Earendil has credible strategic and financing validation, but the public record does not yet support underwriting its clinical conversion or economics at a precise price.

Atom Computing

Atom is a credible neutral-atom platform, but sparse public economics and unverified financing terms support research-more rather than a conviction-priced entry.

Walden Robotics

Walden has credible technical and strategic validation, but public proof is too limited to underwrite its reported seed valuation confidently.

Valuation

$1.1B

SPIC Hydrogen Energy

SPIC Hydrogen Energy looks strategically relevant in China's hydrogen equipment chain, but the public record remains too thin to underwrite a current price.

Magic AI

Magic AI has credible long-context coding-model upside, but insufficient public commercial proof and undisclosed financing terms support a research-more stance.

Emergent

Emergent shows genuine breakout growth and a credible product wedge, but public evidence still supports tracking rather than a high-conviction buy.

Valuation

$1.5B

Revenue run-rate

$120M

Super.com

Super.com has a credible consumer savings and fintech growth narrative, but opaque segment economics, customer durability, compliance exposure, and capital-stack terms keep the investment posture at track.

Valuation

$1.2B

Revenue run-rate

$200M

Growth

50%

Silicon Box

A technically credible and capital-backed advanced-packaging scale-up whose production progress is offset by substantial financial, customer, and financing-term opacity.

Valuation

$1.6B

Pulumi

Pulumi shows credible platform and adoption potential, but conflicting financing evidence and missing operating metrics keep the investment case at research-more.

Valuation

$1.5B

PixVerse

PixVerse shows strong product and user momentum and a reported valuation above $2 billion, but undisclosed monetization and unit economics keep the company in track territory.

Valuation

$2B

Orca Bio

FDA approval and randomized clinical evidence validate a differentiated transplant therapy, but opaque launch economics and manufacturing execution keep Orca Bio on the watchlist.

D360 Bank

D360 Bank has credible licensing, strategic backing, and fast reported growth, but undisclosed economics and risk metrics keep the case at track rather than buy.

Valuation

$1.6B

Stardust Intelligence

Stardust Intelligence has credible product and financing momentum, but its aggressive reported valuation remains unsupported by independently verified revenue quality, manufacturing economics, delivery scale, and reliability evidence.

SenseTime Medical

SenseTime Medical has credible hospital-platform breadth and financing momentum, but unresolved operating economics and financing terms keep the recommendation at research-more.

Quicktron

Quicktron is strategically credible in warehouse robotics, but the investment case remains research-more until audited economics, customer durability, governance terms, and entry pricing are verified.

Omni Analytics

Omni has a coherent governed-semantic platform and credible founder-market fit, but limited public durability disclosure and bundle pressure support a track stance at the reported $1.5B valuation.

Valuation

$1.5B

Nexthop AI

Nextop AI addresses a real AI-networking bottleneck with credible technical and investor signals, but the public record is too thin to justify aggressive entry at the reported $4.2B valuation.

Valuation

$4.2B

LimX Dynamics

LimX Dynamics has credible product breadth and financing access, but commercialization quality and operating disclosure remain insufficient for a buy recommendation.

Gokin Solar

Track: Gokin Solar shows real manufacturing scale, product transition, and global channel proof, but limited audited disclosure and stressed public-peer economics keep the investment case unverified.

Field AI

Field AI has credible technical differentiation, substantial financing, and concrete deployment signals, but limited public operating disclosure makes the reported 2026 valuation difficult to underwrite.

Valuation

$2B

DeepRoute.ai

DeepRoute.ai has credible OEM deployment momentum, but opaque economics, customer concentration, regulatory exposure, and absent valuation disclosure support tracking rather than buying.

BioMap

BioMap has credible platform and partner validation, but insufficient financial and ownership disclosure for a buy decision.

Aira

Aira has built a credible integrated residential-electrification platform, but execution risk and missing unit-economic and valuation disclosure warrant tracking rather than an aggressive investment conclusion.

Starburst Data

Starburst appears to be a strong private data-infrastructure asset with credible enterprise traction, but current price, retention, concentration, margins, cash, and transaction structure remain too opaque for an unconditional buy.

Valuation

$3.4B

Revenue run-rate

$100M

ARR

$100M

Growth

40%

NRR

130%

Palmetto

Palmetto is strategically interesting with real financing and platform breadth, but the evidence supports research-more rather than an unconditional investment decision.

Genesis Therapeutics

Track: Genesis has meaningful pharmaceutical validation and differentiated platform evidence, but public economics, customer durability, and clinical conversion remain too opaque for a stronger recommendation.

Dataiku

Dataiku has credible late-stage enterprise AI scale and a durable governance-oriented product position, but incomplete current economics and historical valuation evidence support tracking rather than buying.

Valuation

$3.7B

Revenue run-rate

$350M

ARR

$350M

Yanolja

Yanolja merits tracking for its scaled consumer platform and higher-margin enterprise software engine, but disclosure gaps and unresolved regulatory scrutiny limit conviction at the reported valuation levels.

Valuation

$9B

Growth

22%

Sygnum

Sygnum appears strategically credible as regulated digital-asset infrastructure with institutional proof, but the public record still leaves material revenue, retention, concentration, margin, and capital-structure gaps.

Valuation

$1B

Spiber

Spiber remains a strategically differentiated climate-materials platform, but the 2026 management reset and limited disclosure make scale economics and financing durability the central diligence risks.

SmartNews

SmartNews remains a credible consumer media asset with real product and publisher infrastructure, but current audience, financial, capital-structure, and IPO evidence is too incomplete to support a buy recommendation.

Revenue run-rate

$104.5M

Prime Intellect

Prime Intellect shows strong financing, product breadth, and customer traction, but public evidence leaves valuation-critical operating and governance gaps.

Valuation

$1B

Revenue run-rate

$100M

LeapXpert

LeapXpert appears to have a credible governed-communications position and meaningful financing and customer signals, but public disclosure is insufficient to support a confident price-based investment call.

Lead Bank

Lead Bank has differentiated sponsor-bank infrastructure and credible fintech traction, but regulatory, concentration, governance, and financial-disclosure gaps make a price-sensitive track stance more appropriate than an unconditional buy.

Valuation

$1.5B

Karrot

Track: Karrot is a strong local-network consumer platform with improving monetization, but current valuation and international returns remain under-disclosed.

Growth

48%

Kakao Mobility

Kakao Mobility remains strategically important and competitively resilient in Korea, but unresolved regulatory exposure and thin standalone disclosure justify a cautious track stance.

Inertia

Inertia has unusually strong scientific and strategic starting assets, but public evidence does not yet support a price-sensitive investment decision.

Harbinger Motors

Harbinger has credible capital, customer, and product signals, but the public record still supports a track stance because revenue, margins, liquidity, reliability, and scaled delivery remain insufficiently disclosed.

GI Water as a Service

GI Water as a Service appears strategically credible and commercially worth following, but public evidence remains too thin on economics, governance, and financing terms to underwrite the reported unicorn valuation with comfort.

Valuation

$1B

Beeline Medicines

Beeline appears to be a well-capitalized private lupus-first immunology company with credible mechanisms and multiple programs, but public evidence is insufficient for price conviction.

8090

8090 has a credible governed-software thesis and meaningful financing, but public evidence does not yet prove repeatable software economics or justify a valuation-insensitive investment.

Oratomic

Oratomic has credible scientific ambition and exceptional reported capital backing, but remains a high-risk, pre-revenue quantum hardware bet that is not yet underwritable.

Valuation

$5.5B

Proxima Fusion

Proxima Fusion has strong funding, institutional backing, and differentiated stellarator IP potential, but its pre-revenue valuation still depends on unproven technical and commercialization milestones.

Neara

Strong utility workflow evidence supports continued diligence, but opaque financials and a stretched recorded valuation argue against underwriting today.

Valuation

$712M

Instabase

Instabase has credible enterprise document-AI workflow depth and meaningful financing, but valuation reset, security follow-up, and limited operating disclosure support a cautious track stance.

Valuation

$1.2B

Tandem

Tandem/Forus shows meaningful prescription-access traction and strategic value, but the reported $1 billion valuation remains difficult to underwrite without reconciled financing, margin, concentration, and governance disclosure.

Valuation

$1B

Revenue run-rate

$50M

Stori

Research more: Stori shows meaningful financing access, product breadth, and reported customer scale, but fair valuation is more defensible than a strong buy until portfolio economics, cohorts, partner dependence, and current valuation are verified.

Valuation

$1.3B

KnowBe4

KnowBe4 has meaningful scale and recurring-revenue visibility, but leverage, active risk clustering, and limited private-company disclosure support research-more rather than a buy conclusion.

Valuation

$4.6B

Revenue run-rate

$600M

ARR

$367.7M

Flying Tulip

Flying Tulip has a differentiated integrated DeFi design and meaningful financing history, but should remain tracked until independent assurance, commercial traction, and current valuation evidence improve.

Valuation

$1B

terralayr

Terralayr has credible capital, utility counterparties, and German BESS scale, but its undisclosed valuation and thin financial disclosure prevent a price-sensitive investment call.

I-TRACING

I-TRACING has credible scale and a broad cybersecurity-services platform, but integration, disclosure, and operating-control gaps keep the refresh recommendation at track.

Redaptive Inc.

Redaptive has a credible financing-enabled deployment platform, but current public evidence does not support a confident entry price or underwriting of operating cash conversion.

The Open Platform (TOP)

High-upside Telegram and TON distribution leverage is offset by opaque economics, structure, and regulatory execution risk.

Valuation

$1B

Xona Space Systems

Xona has a differentiated LEO navigation infrastructure thesis and meaningful financing and regulatory milestones, but private operating metrics and valuation evidence remain too incomplete for a buy recommendation.

Blacksmith

Blacksmith shows strong reported demand and infrastructure differentiation, but insufficient disclosure for a confident investment or valuation decision.

Valuation

$1B

Eka Robotics

Eka Robotics has a credible force-aware robotics thesis and substantial reported financing, but commercial scale and production economics remain unproven.

Valuation

$1.5B

Sigma Computing

Sigma Computing appears to be a credible scale-stage warehouse-native analytics company, but private operating metrics and valuation terms remain too incomplete for a high-conviction underwriting call.

Valuation

$3B

Revenue run-rate

$200M

ARR

$200M

Growth

100%

StockX

StockX is a scaled authenticated-resale platform with clear marketplace relevance, but current financial quality, trust-cost metrics, and cap-table detail remain too thin for a high-confidence valuation.

Valuation

$3.8B

Oasis Security

Oasis Security has credible strategic relevance in non-human identity security, but opaque operating metrics and conflicting acquisition-status evidence support continued diligence rather than outright conviction.

Nowports

Nowports has a credible regional logistics platform and historical customer and funding traction, but current economics and risk controls remain too opaque for a buy recommendation.

Valuation

$1.1B

Klook

Track Klook: the marketplace shows meaningful scale and regional breadth, but valuation, retention, governance and cash-conversion uncertainty still warrant diligence before underwriting.

Revenue run-rate

$541M

Keyfactor

Keyfactor appears to be a credible, technically differentiated private trust-infrastructure asset, but incomplete current valuation and operating disclosure supports research-more rather than an unconditional buy.

ARR

$200M

Growth

35%

NRR

120%

Jetti Resources

Research more: Jetti has credible strategic and commercial deployment proof, but the stale valuation mark and missing company-level financial and contract disclosure prevent a confident investment decision.

Valuation

$2.5B

Expel

Expel looks like a credible premium MDR operating asset, but the current price should remain uncommitted until private confirmation of retention, margins, concentration, liquidity, and terms.

Valuation

$1B

Revenue run-rate

$142.2M

Docplanner

Docplanner merits continued diligence for its scale and integrated workflow position, but public evidence does not support a current priced recommendation.

Valuation

$1B

Datavant

Datavant appears to have a strategically important healthcare-data connectivity position, but public evidence remains too thin on current economics to underwrite a premium valuation with high conviction.

Acko

Acko has a credible digital-insurance and embedded-distribution platform with meaningful scale, but unresolved entity scope, regulatory remediation, profitability, and IPO-economics questions keep it on a research-more watchlist.

Abound

Abound shows credible lending scale, profitability, and differentiated open-banking underwriting, but the investment case remains research-more because valuation, funding structure, loan-book quality, and governance depth are not publicly reconciled.

Yassir

Research more: Yassir shows credible regional platform breadth and distribution signals, but current economics, financing terms, liquidity, and regulatory execution remain too opaque for a price-supported investment.

Tripo AI

Tripo AI has credible product breadth and financing momentum, but opaque operating economics and valuation terms make it a tracking opportunity rather than a fully underwritable investment.

Mirador Therapeutics

Mirador combines substantial private financing and a credible precision-immunology platform with a broad clinical pipeline, but public information remains too opaque on valuation, cash runway, and clinical proof to support a buy recommendation.

M-KOPA

M-KOPA has credible pan-African scale and a compelling asset-finance-to-credit model, but public disclosure is not sufficient to underwrite a premium valuation.

Revenue run-rate

$600M

Growth

45%

Konfío

Konfío appears to be a scaled, institutionally financed SME-finance platform with credible product breadth, but missing current credit, profitability, ownership, and valuation evidence warrants research-more rather than a price-insensitive buy.

General Intuition

General Intuition has a differentiated gameplay-data and research thesis, but the reported $6.2 billion valuation is ahead of public proof on revenue, customer durability, and transfer to physical-world deployments.

Valuation

$6.2B

Bambu Lab

Bambu Lab has a differentiated and increasingly scaled 3D-printing ecosystem, but financial opacity, control disputes, and unverified valuation support tracking rather than a buy call.

Augment

Augment built a differentiated enterprise coding proposition and attracted substantial financing, but limited public economics and uncertain transaction terms support a track posture.

XAG Technology

XAG combines real agricultural-robotics depth, international deployment signals, and a reported profit turn, but competition, cash conversion, governance, customer durability, and valuation opacity keep the opportunity at track.

Volant Aerotech

Volant is a serious, well-funded passenger-eVTOL contender with meaningful technical and commercial progress, but certification, cash visibility, contract quality, and unit economics remain insufficiently verified for an investment-grade underwriting decision.

Valuation

$1.5B

Tongdun Technology

Tongdun has strategic relevance in risk-control infrastructure, but limited current disclosure and unresolved legal, customer, and valuation questions warrant further research before investment.

Tengden

Tengden has credible large-UAV engineering and strategic-market relevance, but persistent losses, concentrated and opaque demand, and policy exposure prevent a fully underwritten investment case.

Norm Ai

Norm Ai has a differentiated full-stack legal-AI model and strong financing validation, but undisclosed operating metrics and unresolved legal-structure, governance, and customer-concentration questions keep the opportunity at track rather than buy.

Valuation

$1.2B

inDrive

inDrive has differentiated global scale and expanding service optionality, but conflicting financing marks and missing audited economics make a price-sensitive investment case premature.

Fox ESS

Fox ESS has credible residential-storage scale and reported profitability, but Europe concentration, regulatory exposure, and thin valuation and governance disclosure support tracking rather than an executable investment call.

FINN

FINN has built meaningful car-subscription scale and financing access, but its reported unicorn valuation already assumes strong execution while fleet economics, liquidity, and public disclosure remain unresolved.

Envision AESC

Envision AESC has enough customer and plant proof to matter, but the public file still does not justify premium underwriting without audited revenue, margin, leverage, and cap-table evidence.

Blackpoint Cyber

Blackpoint Cyber has a credible MSP-first MDR position, but current public evidence is insufficient to underwrite valuation or financial returns precisely.

BrainCo

BrainCo has credible neurotechnology breadth and financing scale, but public evidence does not support a company-specific valuation or buy decision.

Safe Security

Safe Security has credible category and financing signals and a broad enterprise cyber-risk platform, but limited financial and independent operating evidence supports tracking rather than an unconditional buy.

Meril Life Sciences

Meril is a scaled, export-oriented Indian medtech platform with strong reported growth and profitability, but litigation, capital intensity, and incomplete private-company disclosures keep the opportunity at Track.

Valuation

$6.6B

Growth

40.3%

ABLY Corporation

Research more: ABLY has credible fashion-commerce scale and improving reported 2025 performance, but opaque private-company economics, unresolved financing terms, and execution and regulatory risks limit underwriting confidence at the reported valuation.

Valuation

$2.1B

Growth

10.6%

LINE MAN Wongnai

Research more: LINE MAN Wongnai has credible Thai scale, ecosystem breadth, and 2025 revenue growth, but current public evidence remains too thin on audited cash economics, capital-structure terms, and subsidy-normalised cohorts to support a premium entry valuation.

Growth

21%

Nearfield Instruments

Nearfield has real technical, customer, and financing proof, but public operating disclosure remains too thin to underwrite the reported valuation as a buy.

Valuation

$1.6B

Even Realities

Even Realities is credible enough to keep on an active diligence list, but public evidence does not justify paying through the reported $1 billion valuation without deeper private economics and term verification.

Valuation

$1B

Freenome

Freenome has reached a public listing and FDA-approved CRC product milestone, but limited operating disclosure and execution risk warrant research-more rather than a price-insensitive buy.

COOWA

COOWA shows unusually strong reported deployment and operating scale for an urban-robotics company, but the evidence is not yet sufficient to underwrite its reported valuation without audited economics and independent technical proof.

Valuation

$3B

Revenue run-rate

$140M

Zhijian Power / 至简动力 / Simplexity Robotics

Simplexity Robotics merits research-more status: financing and technical signals are strong, but public evidence still does not establish paid deployments, recurring revenue, safety performance, or a defensible company valuation.

Advanced Digital Gaming Technology

ADGT has credible sponsor backing and a differentiated regulated-market thesis, but insufficient public operating and valuation evidence for a buy recommendation.

Ollin Biosciences

Ollin has strong disclosed financing and encouraging early clinical differentiation, but opaque economics and an undisclosed valuation keep the recommendation at track rather than conviction underwriting.

Nio GeniTech

Nio GeniTech has strategic technology and policy tailwinds, but the current public record still provides less commercial and financial proof than a price-sensitive investment decision requires.

eSentire

eSentire has a credible differentiated MDR proposition and broad customer proof, but the public record is insufficient to underwrite valuation or recurring-revenue durability.

Huihe Healthcare

Huihe appears to be a technically credible cardiovascular-device platform, but the public record is too incomplete to underwrite a confident valuation or commercial-scale investment decision.

Tessera Therapeutics

Tessera has reached clinical-stage execution with a differentiated but unproven Gene Writing platform, warranting a track or research-more stance until first-in-human data and financial runway become clearer.

Valuation

$1.7B

Xingyun Group (行云集团)

Xingyun Group has meaningful cross-border infrastructure and historical financing scale, but opaque parent financials, unresolved governance linkage, and high compliance exposure keep the investment view at research-more rather than buy.

Valuation

$2B

Sudu Technology

Sudu Technology has credible technical and financing signals but remains a high-risk, pre-commercialization opportunity because production performance, customer traction, and valuation inputs are not publicly established.

Zankore

Zankore has credible strategic sponsorship and an ambitious AI-compute plan, but its financing scale currently runs ahead of disclosed operating and commercial proof.

Namirial

Namirial has credible European trust-services scale and strategic momentum, but current valuation and operating quality cannot be underwritten from public evidence alone.

Sunwoda Electric Vehicle Battery Co., Ltd.

Track Sunwoda EVB: credible scaled OEM traction is offset by opaque standalone economics, a lower nominal 2026 financing mark, and unresolved quality and recall exposure.

Square Yards

Square Yards has credible scale and improving operating leverage, but opaque financing terms and unresolved pre-IPO controls make the security unready for an investment decision.

Valuation

$1B

Revenue run-rate

$223M

Growth

48%

RedotPay

Research more: RedotPay has credible product breadth and company-reported payment scale, but audited economics, customer quality, partner resilience, and the outcome of a material contested lawsuit are not yet underwritable.

Valuation

$1B

Revenue run-rate

$180M

Redo

Redo has credible post-purchase breadth, 4,500+ company-reported brands, and $81 million of new capital, but opaque economics and unresolved fee-regulation exposure make the reported $1.25 billion valuation difficult to underwrite.

Valuation

$1.3B

Noetix Robotics

Track Noetix as an affordability-led humanoid contender, but require primary proof of deliveries, safety, unit economics, and capitalization before investing.

Navi Technologies

Track Navi: lending scale and UPI distribution are meaningful, but consolidated losses, regulatory history, and unverified financing and unit economics prevent a buy recommendation.

Growth

16%

Leju Robotics

Leju shows credible product and shipment momentum, but weak primary disclosure, unproven repeat industrial demand, and unavailable IPO terms make further diligence necessary before investment.

Gilmour Space Technologies

Research more: Gilmour has scarce sovereign-space infrastructure and fresh institutional backing, but orbital reliability, revenue-bearing backlog, and runway remain unproven.

Valuation

$721M

Galaxy Bot

Galaxy Bot has a credible industrial robotics foothold and strong capital backing, but missing operating, contract, safety, and security-rights data prevent underwriting its reported valuation.

Valuation

$3B

Blip

Blip has credible product breadth, institutional backing, and operating scale, but financial opacity and conflicting valuation evidence prevent a defensible investment price.

DexForce

DexForce merits further diligence because its integrated simulation-to-robot stack, financing, and deployment signals are promising, but the reported unicorn valuation is not yet supported by audited economics, independently verified production reliability, or durable customer evidence.

Valuation

$1.5B

Beacon Software

Beacon's capital access and AI-enabled acquisition thesis are credible, but opaque consolidated economics, integration outcomes, and current pricing keep the company in research-more territory.

Aaru

Aaru has credible enterprise and validation signals, but its reported valuation materially outruns the public economics and proof package.

Valuation

$1.5B

Salla

Salla has credible localized product-market scale and institutional backing, but absent valuation terms, audited economics, retention, and control evidence prevent a price-sensitive investment decision.

Zero Hash

Zero Hash merits continued tracking for its integrated regulated platform and institutional distribution, but missing economics and financing terms prevent an investable price conclusion.

Valuation

$1B

RunPod

Research more: RunPod combines rapid company-reported growth, broad developer adoption, and competitive GPU pricing with unresolved unit-economics, reliability, compliance-scope, retention, and valuation evidence.

Valuation

$1B

Revenue run-rate

$325M

ARR

$325M

Growth

90%

NRR

120%

ModRetro

ModRetro's credible enthusiast products and widening physical-media platform merit continued tracking, but the reported $1 billion valuation is not underwritable without primary financing terms and audited operating economics.

Valuation

$1B

Kopi Kenangan

Kopi Kenangan has demonstrated regional scale and reported profitability, but unaudited economics and an unconfirmed premium valuation keep the investment recommendation at track rather than buy.

Valuation

$1.3B

Revenue run-rate

$184M

Growth

45%

Element Labs

Element Labs pairs exceptional semiconductor pedigree with strong capital access, but a reported valuation above $4 billion is not yet supported by public product, customer, or financial proof.

Egnyte

Egnyte is a scaled, strategically relevant content platform, but conflicting valuation marks and unresolved financial and security evidence make further research necessary before underwriting an investment.

CtrlS

CtrlS is a scaled domestic data-center operator with contracted demand and institutional backing, but a full valuation and return case remains blocked by debt-intensive expansion and private-company opacity.

Valuation

$4.7B

Growth

16.6%

Core Automation

Core Automation has credible frontier-AI talent and technical ambition, but absent commercial proof and unresolved financing terms make the reported valuation too uncertain for conviction.

Valuation

$4B

Cadence

Cadence has scaled an embedded clinical-AI care model, but reimbursement exposure and missing decision-grade financial, retention, security, and regulatory evidence support further research rather than investment at the reported private-market valuation.

Valuation

$1.2B

Apeel Sciences

Apeel has credible post-harvest products and international optionality, but commercial contraction and absent current financial, capitalization, and retention evidence make a priced investment premature.

Valuation

$2B

X Square Robot

X Square Robot has credible full-stack technology, strong financing access, and early deployment signals, but opaque economics, limited independent validation, and a stretched valuation make research-more the appropriate stance.

Valuation

$2.8B

VoltaGrid

VoltaGrid has credible hyperscale demand, sponsor backing, and emerging operating proof, but investment underwriting remains blocked by concentration, leverage, permitting risk, and absent audited economics.

Sudo AI

Sudo AI merits continued tracking for its simulation-first manipulation platform and financing momentum, but the reported valuation above US$2 billion is not underwritten by public commercial, financial, or production evidence.

Valuation

$2B

Solace

Solace has credible national scale and widening reimbursed distribution, but absent audited economics, payer durability, security assurance, and financing terms keep the opportunity at track rather than invest.

Valuation

$1B

Rokid

Rokid has credible product and channel momentum, but privacy-control questions and the absence of audited economics, current capitalization, and primary exit evidence make it a high-risk company to track rather than underwrite today.

Valuation

$1B

Nordic Knots

Nordic Knots shows credible premium-brand momentum and rapid reported growth, but a third-party $2.2 billion valuation estimate is not underwritable without audited economics, retention, store payback, and capital-structure terms.

Valuation

$2.2B

Growth

85%

Mesh

Mesh has credible product and distribution proof in a growing crypto-payments category, but opaque economics, control evidence, and rollout status make the $1 billion financing mark stretched rather than independently validated.

Valuation

$1B

Revenue run-rate

$52M

LiveKit

LiveKit is strategically relevant voice-AI infrastructure, but the $1 billion financing mark remains stretched without verified revenue, margins, retention, and concentration.

Valuation

$1B

Linkerbot

Linkerbot shows credible product breadth, financing access, and reported shipment momentum, but its USD 3 billion valuation cannot be underwritten without audited economics, customer verification, and independent scale evidence.

Valuation

$3B

Kapital Bank

Kapital has credible regulated-bank scale and a broad SME platform, but the reported $2.0 billion valuation is not underwritten by public consolidated economics, credit quality, cap-table terms, or completed Intercam integration evidence.

Valuation

$2B

Global Eggs

Global Eggs is a strategically credible multinational egg platform, but the announced US$8 billion valuation is stretched until audited earnings, leverage, and transaction terms are disclosed.

Valuation

$8B

D-Robotics

Fresh capital and reported deployment scale establish product relevance, but financial opacity, regulatory route-to-market exposure, and an undisclosed current valuation support only a Track recommendation.

Starcloud

Starcloud merits continued diligence after credible orbital-compute proof, but its $2.3 billion financing mark is expensive relative to still-missing commercial, reliability, regulatory, and unit-economic evidence.

Valuation

$2.3B

Venice AI

Venice AI combines unusually strong reported early traction with a clear privacy-led wedge, but missing assurance, revenue-quality, retention, and financing evidence make it a track rather than an invest decision.

Valuation

$1B

Revenue run-rate

$70M

Rox

Rox shows credible enterprise product and financing momentum, but the reported $1.2 billion valuation is not underwritable without verified current revenue, retention, margins, deployment economics, and financing terms.

Valuation

$1.2B

Joulent

Track Joulent as a strategically validated but high-risk infrastructure platform whose roughly $5 billion implied value remains unproven until Kilby is fully funded and de-risked.

Valuation

$5B

Beren Therapeutics

Track Beren through the November 2026 FDA decision: regulatory optionality and launch financing are real, but external-control risk and undisclosed transaction economics prevent an investable valuation.

TensorWave

TensorWave has credible infrastructure and strategic AMD backing, but the $1.55 billion reference remains stretched without audited economics, utilization, customer quality, and financing terms.

Valuation

$1.6B

Generalist AI

Track Generalist AI: the team, capital base, and cross-hardware model thesis are compelling, but independent deployment proof and commercial economics remain insufficient for price underwriting.

Valuation

$2B

Town

Town shows unusually fast company-reported traction and ample financing, but missing retention, unit-economics, security-control, and financing-term evidence prevents underwriting the $1 billion mark.

Valuation

$1B

Recursive Intelligence

AlphaChip founder pedigree and $335 million of reported funding justify continued diligence, but a $4 billion valuation remains ahead of public customer, revenue, and Ricursive-specific production proof.

Valuation

$4B

Oxide

Oxide shows differentiated technology, substantial announced financing, and reported demand, but private operating economics and undisclosed round terms make the investment unpriceable without further diligence.

Mosyle

Mosyle merits continued diligence for its focused Apple platform and adoption signals, but financial opacity and conflicting scale and financing records prevent a priced investment decision.

JSW One MSME

JSW One has meaningful industrial-procurement scale and strategic backing, but the reported private valuation remains stretched without audited economics, current security terms, credit cohorts, and customer durability.

Valuation

$925M

Dash0

Dash0 has credible founder-market fit, standards-native product depth, and adoption momentum, but its $1 billion price is not underwritable without primary financial, customer-quality, control, and financing-term evidence.

Valuation

$1B

Cart.com

Cart.com has credible product breadth, operating scale, named customers, and institutional backing, but opaque financials and financing terms prevent a defensible entry-price decision.

Valuation

$1.6B

Axiom

Axiom has credible proof-first technology, research execution, and financing, but its $1.6 billion financing mark remains ahead of publicly verifiable commercial evidence.

Valuation

$1.6B

AIsphere

AIsphere's product reach and financing momentum justify continued diligence, but absent audited economics, governance evidence, and entry terms preclude a buy call.

ARR

$40M

Advanced Machine Intelligence

AMI combines exceptional research capital and credible technical leadership with an expensive entry valuation that remains ahead of public product, customer, economics, and governance proof.

Valuation

$3.5B

Upscale AI

Track Upscale AI rather than buy at the reported $2 billion mark until production adoption, operating economics, technical performance, and financing terms are verified.

Valuation

$2B

Tibber

Tibber has credible smart-energy adoption and residential-flexibility scale, but opaque current economics, financing rights, and security remediation keep the case at research-more.

OYO

Research more: OYO's reported profitability turn and global scale are investable signals, but leverage, unresolved proceedings, execution risk, and a stretched $7-8 billion IPO target prevent price-specific underwriting.

Growth

47%

Nimble Robotics

Nimble has credible robotic-3PL and strategic proof, but public evidence does not yet support underwriting its valuation, utilization, or unit economics.

Moloco

Moloco shows credible product breadth and operating scale, but missing current financials, ownership, and entry terms keep the investment decision at research-more.

Mirendil

Mirendil combines an experienced frontier-AI team, top-tier backing, and meaningful compute infrastructure with a reported billion-dollar valuation that remains unsupported by public product, customer, or economic proof.

Valuation

$1B

ModelBest

ModelBest has credible edge-model and automotive deployment signals, but the reported unicorn-threshold price is not underwritable without audited commercial metrics and financing terms.

Keyrock

Keyrock has credible strategic breadth and a corroborated $1.1 billion financing marker, but absent audited economics, customer-quality data, round terms, and primary acquisition records make the valuation stretched and the investment case research-more.

Valuation

$1.1B

Inceptio Technology

Inceptio's commercial deployment evidence merits continued tracking, but absent audited economics, current valuation, and independent assurance prevent entry-price underwriting.

Firmus Technologies

Firmus has credible strategic backing and demand signals, but the reported valuation outruns the public evidence for operating economics, financed delivery, and durable utilization.

Valuation

$10.5B

Digital Asset

Track Digital Asset for its differentiated institutional product architecture and strategic backing, but do not underwrite the reported valuation until audited economics, production-customer evidence, and financing terms are available.

Valuation

$2B

Brevo

Brevo appears to be a scaled, reportedly profitable customer-engagement platform, but public evidence is insufficient for a price-specific investment recommendation.

Assort Health

Assort Health shows credible patient-access product breadth and commercial pull, but its reported $1.2 billion financing mark remains unsupported by the public operating, safety, and security evidence required for an investment decision.

Valuation

$1.2B

AppsFlyer

AppsFlyer is scaled and strategically relevant, but opaque economics and unresolved post-incident evidence support tracking the company rather than underwriting a buy today.

Valuation

$2.7B

AlphaSense

Research more at the $7.5 billion reference: AlphaSense has strong scale, enterprise adoption, and product breadth, but private economics and security terms remain too incomplete for a buy recommendation.

Valuation

$7.5B

ARR

$700M

Wonderful

Wonderful has credible product breadth, financing strength, and enterprise deployment momentum, but a roughly 71x valuation-to-annualized-revenue signal and missing retention, margin, concentration, control, and financing-term data make further research necessary before underwriting an entry.

Valuation

$5B

Revenue run-rate

$70M

Unico

Track Unico for its substantial identity-verification scale and international expansion, but defer investment pricing until current financials, ownership terms, and the sealed Serasa-related dispute can be underwritten.

Valuation

$2.6B

Tide

Tide has achieved meaningful SME distribution and product breadth, but the USD 1.5 billion financing mark is not yet supported by decision-grade evidence on consolidated economics, retention, partner concentration, or investor terms.

Valuation

$1.5B

Slash

Research more: Slash shows substantial reported scale and a broad financial operating platform, but a stretched $1.4 billion valuation precedes the audited economics, retention, control assurance, and ownership terms needed for an investment decision.

Valuation

$1.4B

Revenue run-rate

$250M

ShareChat

Track: ShareChat's vernacular portfolio and operating repair merit continued diligence, but liquidity, financing terms, audited cash generation, and current valuation remain too opaque for an investment commitment.

Rogo

Rogo shows meaningful institutional adoption, rapid product expansion, and strong financing access, but undisclosed Series D pricing and unverified recurring economics make research-more the supportable decision.

ARR

$53M

Parallel

Parallel has credible agent-web infrastructure, adoption, and production proof, but opaque economics and a rapid valuation step-up keep the company at research-more.

Valuation

$2B

OpenRouter

OpenRouter has credible multi-model scale and strategic relevance, but unresolved transaction terms and unaudited economics make research-more the only supportable current stance.

Valuation

$1.3B

Granola

Granola's differentiated bot-free workflow and enterprise-context ambition merit continued diligence, but the $1.5 billion financing mark is not supported by disclosed revenue, retention, margin, or cash data.

Valuation

$1.5B

GSR

GSR has credible institutional and product momentum, but absent audited economics, financing terms, and control evidence keep the opportunity in research-more territory.

GetYourGuide

GetYourGuide has credible marketplace scale and company-reported adjusted-EBITDA profitability, but missing audited economics, capital terms, and normalized supplier and customer outcomes make the investment research-more rather than buy.

Valuation

$2B

Exiger

Exiger has credible product breadth, regulated-market positioning, and company-reported customer scale, but financial, retention, and transaction opacity make the reported valuation context too weak for price approval.

Bose Quantum

Bose Quantum has credible financing, product, factory, and deployment signals, but missing commercial economics, production proof, and transaction terms make further diligence necessary before pricing an investment.

Black Forest Labs

Black Forest Labs is a technically credible visual-AI contender with strong financing and distribution signals, but the latest private valuation remains unvalidated without audited economics, concentration data, and control evidence.

Valuation

$3.3B

Revenue run-rate

$96.3M

Andromeda

Andromeda shows meaningful reported GPU-marketplace scale, but its $1.5 billion valuation remains ahead of public evidence on margin quality, concentration, controls, and ownership terms.

Valuation

$1.5B

Revenue run-rate

$100M

Profound

Profound has credible enterprise product breadth and exceptional financing momentum, but its $1.8 billion mark is stretched against public evidence that omits audited recurring revenue, retention, margins, and security-level economics.

Valuation

$1.8B

PaleBlueDot AI

Track PaleBlueDot AI: its broad compute platform, financing access, and reported contract demand are credible signals, but the $3.2 billion mark is stretched without audited conversion, margin, liquidity, and security-term evidence.

Valuation

$3.2B

Flapping Airplanes

Flapping Airplanes is a differentiated, well-funded AI research bet, but investment underwriting should remain at research-more until its data-efficiency thesis, commercial path, governance, and entry price are supported by primary evidence.

DeepWay

DeepWay has reached meaningful electric-truck scale, but thin margins, continuing losses, concentrated dependencies, and undisclosed transaction terms make it a diligence-gated tracking opportunity rather than an invest-now case.

Growth

97.6%

SVOLT Energy Technology

SVOLT combines real manufacturing scale and an active semi-solid roadmap with Europe retrenchment and thin public financial disclosure, so the current view remains research-more rather than buy.

Slate Auto

Slate has unusually strong sponsor backing for an affordable-EV startup, but public evidence still supports only a track stance because launch execution, conversion, and valuation remain unresolved.

SecurityScorecard

SecurityScorecard remains a category-defining cyber risk ratings platform with real enterprise adoption and credible expansion into managed services and AI workflows, but its current economics are still too opaque to upgrade beyond a track recommendation.

Valuation

$1B

Revenue run-rate

$150M

ARR

$150M

Ro

Ro remains a scaled D2C healthcare platform with real GLP-1-driven growth and vertical integration, but the stale $7B mark, opaque margins, and manufacturer dependence keep it in track territory rather than buy territory.

Valuation

$7B

Revenue run-rate

$598M

Growth

66%

Pine Labs

Track: Pine Labs is a scaled Indian merchant-commerce platform with improving profitability and credible valuation upside, but tax, breakage, and disclosure risks still block a cleaner buy case.

Valuation

$2.2B

Revenue run-rate

$308M

Growth

19%

Outrider

Outrider remains one of the more credible autonomous yard-operations specialists in the market, but public opacity around valuation, revenue, pricing, and customer concentration still keeps the investment case below underwriting grade.

GoCardless

GoCardless has a credible bank-payments franchise and improving profitability, but the completed Mollie acquisition, opaque transaction economics, and governance gaps keep the case at Track.

Growth

22%

Firestorm Labs

Firestorm pairs a differentiated expeditionary-manufacturing thesis with real defense traction and fresh capital, but public underwriting is still blocked by opaque valuation, financial disclosure, and customer-concentration data.

Factorial Energy

Factorial is a technically credible solid-state battery platform company, but its public disclosure still does not underwrite revenue quality or capital efficiency well enough to call it a clear buy.

Valuation

$1.3B

Chando

Chando remains a real, scaled beauty business, but the refreshed evidence still supports only a track stance because brand concentration, family control, and missing operating detail keep the valuation fair rather than clearly attractive.

Valuation

$1B

Revenue run-rate

$745M

Growth

15.6%

BlueVoyant

BlueVoyant looks like a real late-stage cyber-defense platform with material customer scale and broad service breadth, but the market still lacks a reconciled valuation, cap table, and audited economics, so track remains the right posture.

Signifyd

Signifyd is a real guarantee-backed commerce protection platform, but stale valuation references and opaque unit economics still justify tracking rather than buying.

Valuation

$1.3B

AscenPower

AscenPower has a credible SiC manufacturing buildout and real funding momentum, but the public record still leaves revenue quality, customer conversion, and margin durability unresolved.

Science Corporation

Science has entered early European commercialization with PRIMA and a $230M Series C, but the lack of disclosed reimbursement economics, revenue, and governance detail still justifies a track call at a stretched valuation.

Valuation

$1.5B

Rentberry

Rentberry looks like a real rental-workflow product with continued capital access, but public evidence still leaves valuation, governance, and monetization questions too open for a more aggressive stance.

Valuation

$200M

Reflection AI

Reflection AI has a real product launch and serious capital access, but public revenue, customer, and governance proof are still too thin to justify treating the company as conventionally underwritten software.

Valuation

$25B

Merama

Merama remains a scaled Latin American brand holdco, but opaque leverage, inconsistent public metrics, and a concentrated six-brand portfolio keep the case at TRACK.

Mammoth Biosciences

Mammoth remains a high-upside CRISPR platform with partner validation, but public disclosure is still too thin to underwrite revenue quality or valuation confidence.

Infinite Reality

Infinite Reality has assembled real immersive-commerce and media assets, but the gap between its confirmed fundamentals and its self-reported valuation remains so extreme that the equity case is currently dominated by governance, legal, and financing downside rather than platform upside.

Valuation

$5.1B

Highway

Highway has credible category leadership and customer adoption in freight fraud prevention, but public disclosure is still too thin for a price-sensitive investment call.

Endless

Endless is a credible but still opaque Web3 infrastructure bet: the financing signal is real, but public evidence on revenue, users, governance, and treasury quality is still too thin to underwrite the $1B mark.

Valuation

$1B

eMed

eMed still looks like a credible employer GLP-1 scale-up, but the refreshed public record leaves revenue quality, margin durability, customer concentration, and governance too opaque to justify a higher-conviction call.

Valuation

$2B

Cosm

Cosm has real strategic validation and a clearer multi-venue platform story, but it still belongs on the track list because valuation, unit economics, and financing terms remain opaque.

Valuation

$1B

CAIT

CAIT remains a strategically credible CATL-backed chassis platform with real OEM traction and fresh capital, but the public record still stops short of underwriting its standalone economics or governance independence.

Valuation

$1.4B

9fin

9fin has built a credible AI-native platform with proven penetration across all top-10 global investment banks and 350+ institutions, warranting a Track stance while financial opacity prevents a clean underwrite of the $1.3 billion valuation.

Valuation

$1.3B

Viam

Viam offers a credible robotics control-plane platform with visible partner-led momentum, but undisclosed revenue, valuation, and customer retention keep the call at track.

Tianji

Tianji looks like a real, scaling robotics hardware supplier, but the public financial evidence still lags the May 2026 valuation.

Valuation

$1.5B

Tekion Corp

Tekion remains the leading cloud-native DMS challenger, backed by strategic OEM investors and strong enterprise adoption, but broad displacement of incumbents still depends on proving large-scale migrations, unit economics, and profitability.

Valuation

$4B

ARR

$280M

Growth

97%

NRR

112%

Sun King

Sun King remains a scaled, category-leading PAYG solar platform with strong distribution and financing access, but public financial and credit disclosure is still too thin to support a buy case.

SmartHR, Inc.

SmartHR remains a strong Japanese HR-platform story, but current private-company economics and governance detail are still not public enough for a premium valuation call.

Valuation

$1B

SHEIN

SHEIN is large enough and operationally capable enough to matter, but the 2026 IPO reset, slower growth, and persistent legal and regulatory overhang keep the risk/reward balanced rather than compelling.

Valuation

$26.8B

Revenue run-rate

$41.8B

Growth

8%

RapidSOS

RapidSOS remains a credible category leader in emergency-response interoperability, but thin public economics and a messy financing record still justify a research-more stance.

Valuation

$1B

Motive

Motive has meaningful scale, enterprise momentum, and product breadth, but the current valuation and financing economics are still too opaque for a buy call.

ARR

$600M

Growth

30%

NRR

120%

Juniper Square

Juniper Square remains a credible private-markets category leader, but valuation discipline still depends on private diligence because audited economics and cap-table detail are not public.

Valuation

$1.1B

Revenue run-rate

$139.8M

ARR

$139.8M

Growth

29%

Infobip

Scaled CPaaS leader with real profitability and distribution momentum, but opaque private terms keep the call at track rather than buy.

Revenue run-rate

$2.3B

Growth

17%

Fundamental Technologies

Fundamental has real technical and strategic signal, but the current valuation still outruns public operating disclosure.

Valuation

$1.4B

Etraveli Group

Scaled, sponsor-backed flight-commerce infrastructure with real partner validation and EBITDA evidence, but the current price, leverage, and rights package remain opaque enough that research-more is still the right call.

Synchron

Synchron's minimally invasive BCI now has deeper patient evidence and strong funding, but commercial visibility is still too thin for a conviction buy.

Valuation

$1B

nesto

nesto's C$1.47 billion Series E valuation is anchored by genuine operating scale — C$80B+ MUA, C$37B+ 2026 originations, and confirmed profitability — and by high-quality institutional backing from La Caisse and Fidelity, but revenue opacity, balance-sheet funding dependency, and unresolved M3 channel concentration prevent conviction; the evidence supports a track recommendation at a fair valuation.

Valuation

$1.1B

Musinsa

Musinsa combines category leadership, real profitability, and strong Korean fashion consumer mindshare, but the current private/IPO valuation ambition runs materially ahead of disclosed fundamentals and the company still carries regulatory, trust, and international-execution risk.

Valuation

$2.4B

KreditBee

KreditBee has credible scale, profitability, and a fresh unicorn valuation, but public evidence still does not make the April 2026 price look clearly cheap against credit, disclosure, and regulatory risks.

Valuation

$1.5B

Corgi Insurance

Corgi remains a fast-scaling, AI-native startup insurer with real product-market pull and strong funding support, but its public valuation still runs ahead of disclosed carrier economics and claims evidence.

Valuation

$2.6B

ARR

$40M

Blitzy

Blitzy has credible enterprise traction and a well-corroborated $1.4 billion financing mark, but public evidence still leaves revenue quality, customer durability, and unit economics opaque enough to keep the call at track.

Valuation

$1.4B

Tuduoduo

Tuduoduo is a scaled and profitable industrial B2B platform with credible category depth, but unresolved parent-governance, compliance, and disclosure gaps keep the supportable call at research-more rather than buy.

Valuation

$2.2B

Revenue run-rate

$4.1B

Growth

15.6%

Tractian

Credible industrial AI platform with strong customer proof and integrated product design, but incomplete financial disclosure keeps the investment case short of full underwriting.

Valuation

$720M

Shihang Intelligent

Shihang Intelligent shows unusually strong financing, order, and field-validation signals for a 2023-founded marine-robotics company, but opaque valuation, revenue conversion, and regulatory execution keep it in research-more territory.

Neysa

Neysa has credible sovereign-AI positioning and sponsor-backed scale capital, but public evidence still does not justify underwriting a buy at the visible ~$1.4B valuation.

Valuation

$1.4B

SPAN

SPAN's product differentiation and partner momentum remain credible, but limited operating disclosure still supports a track recommendation rather than a buy.

Narwal Robotics

Premium consumer-robotics challenger with real product momentum and scale signals, but still opaque on financials, governance, and margin durability.

Valuation

$2.4B

Revenue run-rate

$200M

Growth

130%

Trackunit

Trackunit remains a category-leading construction telematics and operating-data platform, but limited post-buyout transparency, undisclosed leverage, and persistent execution and privacy risks keep the evidence base from supporting a higher-conviction call.

Valuation

$1.5B

Revenue run-rate

$186.5M

ARR

$119.5M

Growth

10%

Valon

Valon has strong operating proof and fresh capital, but the public package still falls short of underwritten economics.

Valuation

$2.3B

Tensordyne

Tensordyne looks like a real late-stage AI-inference infrastructure company, but the public record still stops short of proving durable customer adoption or a clean financial picture.

Mytra

Mytra combines a differentiated full-pallet warehouse-automation platform with credible deployment proof and strong investor support, but the lack of public financial disclosure and the still-unproven scale economics keep the name in research-more territory.

Valuation

$2B

Mews

Mews looks like a scaled hospitality operating system with real product breadth and strong funding access, but the refreshed evidence still leaves valuation underwriting constrained by missing ARR, take-rate, burn, runway, and governance disclosure.

Valuation

$2.5B

LMArena

LMArena looks like the category leader in AI evaluation, but the $1.7B Series A leaves limited margin of safety until neutrality, governance, and customer-concentration questions are resolved.

Valuation

$1.7B

Revenue run-rate

$30M

Kriya Therapeutics

Kriya looks strategically differentiated and still well funded, but the public record remains too thin on valuation, cash, and human efficacy to justify a more aggressive stance than track.

Just Salad

Just Salad looks like a real scaled concept with differentiated sustainability branding and credible growth momentum, but the current $1 billion mark already prices in strong execution while audited economics, capital-structure details, and retention data remain private.

Valuation

$1B

Revenue run-rate

$195M

Growth

21.9%

Inari Agriculture

Inari remains a technically credible but still commercially opaque seed gene-editing platform, so the refresh supports continued diligence rather than a buy-style call.

Valuation

$2.2B

GalaxySpace (银河航天)

GalaxySpace is one of China's more credible private LEO broadband and satellite-manufacturing platforms, but public disclosure still falls short of what is needed to underwrite a roughly $4.4 billion valuation with confidence.

Valuation

$4.4B

Eve

Eve has clear plaintiff-law workflow fit and strong financing support, but public evidence still leaves revenue quality, retention, and governance too opaque to underwrite the last unicorn mark aggressively.

Valuation

$1.1B

Defense Unicorns

Defense Unicorns has real attributable traction in air-gapped defense software delivery, but the $1B+ Series B valuation still depends on economics the public record does not disclose.

Valuation

$1B

Avatr Technology

Avatr remains a strategically backed premium EV platform with real commercial scale, but 2026 momentum, partner dependence, and opaque valuation terms still support a research-more call.

Growth

98.5%

Altruist

Altruist remains a strategically scarce RIA custody-and-software platform, but the public record still does not justify a clean standalone underwriting case at the reported Vanguard takeout range.

Valuation

$1.9B

Seekr Technologies

Seekr pairs genuine defense and regulated-industry traction with a credible trustworthy-AI platform, but the valuation still looks expensive relative to disclosed revenue and the private-market economics remain opaque.

Valuation

$1.2B

Revenue run-rate

$18M

Impulse Space

Impulse Space has unusually strong public proof for a private orbital-mobility company, but Helios execution and opaque economics still justify a research-more / track stance.

Valuation

$4.3B

Focused Energy

Focused Energy is unusually well capitalized for a pre-commercial fusion developer, but the public record still lacks disclosed valuation terms, customer contracts, and plant-level proof needed to move beyond a research-more stance.

Flourish Inc.

Flourish combines rare founder pedigree with a differentiated energy-efficiency thesis, but public evidence is still far too thin to underwrite a $2.5B pre-product valuation with conviction.

Valuation

$2.5B

Ent

Ent is a well-funded, technically credible workspace security startup with early enterprise adoption signals, but pricing, customer depth, and operating metrics remain too opaque to underwrite aggressively.

DevRev

DevRev remains a structurally differentiated AI-native enterprise platform with founder pedigree and meaningful customer proof, but the public valuation still prices in substantial execution success that is not yet fully demonstrated at scale.

Valuation

$1.2B

Revenue run-rate

$100M

ARR

$100M

Growth

43%

Agrovision

Category-defining premium berry platform with branded distribution scale and strong investor support, but opaque economics and climate-exposed agriculture keep the investment case at a track rather than buy.

Valuation

$1B

Revenue run-rate

$400M

Xoople

Xoople has credible EarthAI positioning and serious backing, but the public record still does not justify underwriting a fresh entry without disclosed valuation terms and stronger commercial proof.

United Imaging Intelligence

United Imaging Intelligence has genuine deployment scale and a credible platform, but public evidence still leaves the reported $1.4 billion valuation hard to underwrite without standalone economics.

Valuation

$1.4B

Trellix

Trellix remains a scaled, PE-backed XDR platform with real enterprise reach, but current public evidence still does not support a clean valuation or full operating underwrite.

TARS Robotics

TARS remains a highly funded humanoid robotics startup with real technical momentum, but public evidence still does not establish revenue, named customers, headcount, or a disclosed post-money valuation.

Skeleton Technologies

Skeleton has real AI-power commercialization and strategic validation, but public economics and cap-table detail are still too thin to underwrite past the latest private mark.

Shrapnel

Shrapnel still looks like a differentiated UE5 extraction shooter with creator-economy and China-access optionality, but the public record leaves revenue, valuation, and operating economics unpriced.

PowerSchool

PowerSchool remains a category-leading K-12 platform, but private-company opacity, breach overhang, and undisclosed leverage keep it in research-more territory.

Valuation

$5.6B

ARR

$701.5M

Growth

17.7%

Onebrief

Onebrief's military-planning wedge and expanding procurement access still support a credible command-software thesis, but the $2.15B headline remains difficult to underwrite without disclosed revenue, margin, or cap-table terms.

Valuation

$2.2B

Noah Medical

Noah Medical has real robotic-bronchoscopy traction and workflow differentiation, but public financial opacity and unresolved quality risk keep it in research-more territory.

Liquid Death

Liquid Death remains a scaled premium beverage brand with broad distribution and a durable marketing moat, but opaque unit economics, concentration risk, and a premium valuation still justify track / research-more at medium confidence.

Valuation

$1.4B

Revenue run-rate

$333M

Growth

27%

JumpCloud

JumpCloud remains a credible consolidation-oriented identity and device-management platform, but the public record still lacks current financial proof and a fresh valuation anchor.

Valuation

$2.6B

Geek+

Geek+ is a public, founder-led warehouse-automation platform with strong 2025-2026 operating momentum, but the right stance remains track because valuation dispersion, disclosure gaps, and competition still limit margin of safety.

Growth

31.6%

Flexe

Flexe remains a category-defining flexible warehousing platform with credible enterprise traction, but stale financing, opaque unit economics, and post-2023 restructuring keep valuation risk elevated.

Valuation

$1B

Revenue run-rate

$91.1M

ARR

$91.1M

Growth

157.3%

Fireflies.ai

Fireflies is a broad AI meeting-workflow company, but its reported $1B+ secondary valuation still lacks public underwriting support.

Valuation

$1B

Factory

Factory looks like a real enterprise software-delivery platform with strong product breadth, marquee customer proof, and a fresh $5 billion financing mark, but the public record still leaves revenue quality, margins, and contract durability too opaque for a firmer underwriting call.

Valuation

$5B

Exa

Exa looks like a real and differentiated agent-search infrastructure company, but the public economics and current $2.2 billion price are still too opaque to justify an invest-now call.

Valuation

$2.2B

Aviatrix

Aviatrix has credible multicloud security technology and real enterprise proof points, but opaque financials, a difficult competitive landscape, and a sharp gap between its 2021 primary valuation and 2026 secondary signal keep the stock in track-not-buy territory.

Valuation

$411M

Revenue run-rate

$85M

ARR

$64M

Growth

81%

webAI

webAI is a differentiated sovereign-AI platform with real public-sector and enterprise proof, but a $2.5B headline valuation and missing operating disclosure keep it in track-and-re-underwrite territory.

Valuation

$2.5B

Stark

Stark shows real strategic momentum in European autonomous strike systems, but the public evidence is still too thin to underwrite the latest private mark as fundamentals rather than scarcity.

Valuation

$3.5B

Scribe

Scribe has credible enterprise workflow adoption and a differentiated AI-context wedge, but public evidence still supports only a cautious underwriting view at the 2025 $1.3B valuation.

Valuation

$1.3B

Revenue run-rate

$100M

ARR

$100M

Reve

Reve's layout-first creative workflow remains differentiated, but the public evidence still does not support a priced investment case.

Prometheus

Prometheus combines extraordinary capital formation with thin public operating proof, so the evidence supports continued diligence rather than paying into the current mark.

Valuation

$41B

PhysicsX

PhysicsX combines credible platform depth and strong financing momentum with public-denominator opacity that keeps the $2.4 billion Series C hard to underwrite from public evidence alone.

Valuation

$2.4B

Growth

100%

Personio

Personio remains a strong European HR platform, but the public evidence still supports track rather than a fresh premium valuation call.

Valuation

$8.5B

Olix

Olix's latest Series B and leadership additions strengthen the story, but the company still lacks public customer, revenue, and benchmark proof to underwrite the valuation with confidence.

Valuation

$3.3B

Odyssey

Odyssey's world-model story looks stronger on product cadence and capital backing, but public evidence still does not disclose revenue, customer conversion, or financing terms well enough to underwrite the valuation cleanly.

Valuation

$1.5B

Nscale

Nscale has assembled one of Europe's most ambitious AI infrastructure platforms, with sovereign AI positioning, elite investors, and Microsoft-anchored demand — but the public record still lacks revenue disclosure, the customer base is hyperconcentrated, leverage is rising, and UK planning friction keeps the current $14.6B valuation in stretched territory.

Valuation

$14.6B

Nord Quantique

Nord Quantique remains a technically differentiated but commercially opaque private quantum-hardware company whose public valuation is buoyed by a May 2026 $30 million round and reported $1.4 billion mark.

Valuation

$1.4B

Greenko Energy

Greenko remains India's leading private renewable platform with differentiated storage assets and strong funding access, but high capex, project execution slippage, and opaque financial disclosure keep the investment case fair rather than cheap.

Valuation

$7.4B

Revenue run-rate

$600M

Growth

13%

Securonix

Securonix remains a strong enterprise cloud-SIEM platform, but public evidence still does not support a purchase-grade valuation or a clean current underwriting model.